What follistatin-344 research covers
Follistatin is a secreted glycoprotein that binds and neutralizes myostatin, the transforming growth factor beta family member that normally limits skeletal muscle growth. Follistatin-344 refers to a specific cDNA construct, 344 amino acids including a 29-residue signal sequence, that has been packaged into adeno-associated virus (AAV) vectors and used in myostatin-inhibition gene therapy research since the mid-2000s. It is one of several follistatin isoforms studied for this purpose, alongside the shorter FS-288 splice variant.
Nearly all follistatin-344 research to date is AAV gene delivery, not injection of a synthetic or recombinant protein. A single vector injection causes muscle cells to manufacture and secrete the follistatin protein locally and systemically over months to years. This distinction matters for anyone encountering follistatin-344 marketed as an injectable research peptide: the published evidence base is built on gene transfer, and no clinical pharmacokinetic data exist for injected synthetic follistatin-344 protein.
How follistatin blocks myostatin signaling
Myostatin (also called GDF-8) signals through activin receptors ALK4 and ALK5, which phosphorylate SMAD2 and SMAD3. Phosphorylated SMAD2/3 forms a complex with SMAD4 and moves into the nucleus, where it represses MyoD and other transcription factors needed for muscle fiber growth. Loss-of-function myostatin mutations in cattle, sheep, and a small number of documented human cases produce pronounced muscle hypertrophy, which is what first identified myostatin as a growth-limiting signal.
Follistatin binds myostatin directly, along with the related ligand activin A, and prevents both from reaching their receptors. Research from Winbanks and colleagues at Monash University, published in the Journal of Cell Biology in 2012 (Winbanks et al., J Cell Biol 2012;197:997-1008), used an AAV vector expressing the FS-288 isoform in mice and found that follistatin-driven muscle hypertrophy still occurred in myostatin-knockout animals. The hypertrophy instead depended on SMAD3 acting through Akt and mTOR signaling, which means follistatin has at least one growth-promoting pathway that operates independently of myostatin blockade itself.
FS-344 versus FS-315 and FS-288: why the isoform matters
Human follistatin is transcribed as a 344-residue precursor. After the signal peptide is cleaved, the two dominant circulating and tissue forms are FS-315, sometimes described as the full mature protein, and FS-288, which is missing the C-terminal 27 residues present in FS-315. That missing segment is acidic and normally shields a basic heparin-binding patch, so its absence in FS-288 leaves that patch exposed.
FS-288 binds tightly to heparan sulfate proteoglycans on cell surfaces and stays largely localized near the tissue where it is produced. FS-315, and the FS-344 gene construct that produces it, has much lower affinity for heparan sulfate and distributes through the circulation instead.
Gene therapy researchers chose the FS-344 construct specifically because systemic distribution was the goal for diseases like muscular dystrophy, where muscle wasting is not confined to a single injection site. A related protein, FSTL3, shares the three-domain follistatin structure and also binds myostatin and activin A. FSTL1 is a separate case: despite the similar name, it carries only a single follistatin-like domain, does not bind myostatin the way follistatin and FSTL3 do, and is studied mainly in cardiac and kidney fibrosis rather than muscle growth. Confusing FSTL1 with follistatin is a common error in secondary sources.
Animal studies: mice and nonhuman primates
The foundational FS-344 gene therapy data come from Haidet and colleagues at Nationwide Children's Hospital, published in the Proceedings of the National Academy of Sciences in 2008 (Haidet et al., PNAS 2008;105:4318-4322). A single intramuscular AAV1-FS344 injection in dystrophin-deficient mdx mice, a standard Duchenne muscular dystrophy model, produced muscle mass increases exceeding 20 percent and dose-dependent gains in grip strength. The effect lasted more than two years from a single injection, with no adverse cardiac or reproductive findings in either sex. A companion review by Rodino-Klapac and colleagues the following year laid out the case for follistatin over other myostatin-blocking approaches then in development (Rodino-Klapac et al., Muscle Nerve 2009;39:283-296).
The same research group moved to a larger animal model in 2009, injecting AAV1-FS344 into the quadriceps of cynomolgus macaques at a total dose of 1 x 10^13 vector genomes in 1.5 mL (Kota et al., Sci Transl Med 2009;1:6ra15). The treated muscle showed durable increases in size and strength, with no adverse immune response detected and no measurable change in reproductive hormone levels. Moving beyond a rodent model to a longer-lived primate with an immune system closer to humans is what supported taking the same vector into a human trial.
The Becker muscular dystrophy trial in humans
Mendell and colleagues at Nationwide Children's Hospital ran the resulting phase 1/2a trial, registered as NCT01519349 on ClinicalTrials.gov and published in Molecular Therapy (Mendell et al., Mol Ther 2015;23:192-201). Six patients with Becker muscular dystrophy received AAV1.CMV.FS344 by direct bilateral injection into the quadriceps, split across two dose cohorts: three patients at 3 x 10^11 vector genomes per kilogram per leg, and three at double that dose.
Improvement on the six-minute walk test, the trial's primary functional measure, ranged from 29 to 125 meters across patients, with the largest gains concentrated in the higher-dose cohort. Muscle biopsies after treatment showed reduced fibrosis, fewer centrally nucleated fibers (a marker of ongoing degeneration and regeneration), and more uniform fiber size compared to baseline. No serious adverse events were reported. The authors describe it as the first gene therapy trial to demonstrate a measurable functional improvement in any form of muscular dystrophy, though the trial was small, uncontrolled, and designed to establish safety and feasibility rather than efficacy.
Research use: form, handling, and what is not established
Because the published FS-344 literature is gene therapy delivered through a viral vector, it does not establish dosing, half-life, or bioavailability for a recombinant follistatin protein handled the way other research peptides are handled: lyophilized, reconstituted, and stored between uses. Anyone working with recombinant follistatin protein in an in vitro or ex vivo research setting should still apply standard peptide handling practices, since improper reconstitution and storage will affect assay results regardless of what the parent gene therapy trials found.
That means verifying reconstituted concentration against the specific molecular weight of the recombinant form in hand, since follistatin fragments and fusion constructs sold for research vary in length and are not interchangeable with the FS-344 vector product described above. The dosing calculator on this site covers concentration, volume, and unit math for that step. Storage conditions also matter more than they might for a small peptide: follistatin is a larger, disulfide-bonded glycoprotein, and the same humidity and freeze-thaw concerns covered in our lyophilized peptide storage guide apply, along with the purity documentation discussed in our certificate of analysis guide. In Indonesia's climate, where ambient humidity accelerates degradation of poorly sealed lyophilized protein, that storage discipline matters more, not less.
No published trial has tested an injectable synthetic or recombinant follistatin-344 protein product in animals or humans as an alternative to the AAV vector approach described here. Claims about dosing, cycle length, or expected effects for such a product are not supported by the literature summarized above.